zinbryta
biogen idec ltd - declizumaba - multipla skleroza - imunosupresivi - zinbryta je indicirana kod odraslih bolesnika za liječenje relapsnih oblika multiple skleroze (rms).
actemra 80 mg/4 ml koncentrat za rastvor za infuziju
roche d.o.o.roche ltd. - tocilizumab - koncentrat za rastvor za infuziju - 80 mg/4 ml - 4 ml koncentrata za rastvor za infuziju sadrži: 80 mg tocilizumaba ( 20 mg/ml )
actemra 200 mg/10 ml koncentrat za rastvor za infuziju
roche d.o.o.roche ltd. - tocilizumab - koncentrat za rastvor za infuziju - 200 mg/10 ml - 10 ml koncentrata za rastvor za infuziju sadrži: 200 mg tocilizumaba (20 mg/ml)
actemra 400 mg/20 ml koncentrat za rastvor za infuziju
roche d.o.o.roche ltd. - tocilizumab - koncentrat za rastvor za infuziju - 400 mg/20 ml - 20 ml koncentrata za rastvor za infuziju sadrži: 400 mg tocilizumaba ( 20 mg/ml )
tyenne
fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresivi - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - limfom, mantel-stanica - antineoplastična sredstva - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
actemra 80 mg/4 ml koncentrat za rastvor za infuziju
roche d.o.o.roche ltd. - tocilizumab - koncentrat za rastvor za infuziju - 80 mg/4 ml - 4 ml koncentrata za rastvor za infuziju sadrži: 80 mg tocilizumaba ( 20 mg/ml )
actemra 200 mg/10 ml koncentrat za rastvor za infuziju
roche d.o.o.roche ltd. - tocilizumab - koncentrat za rastvor za infuziju - 200 mg/10 ml - 10 ml koncentrata za rastvor za infuziju sadrži: 200 mg tocilizumaba (20 mg/ml)
actemra 400 mg/20 ml koncentrat za rastvor za infuziju
roche d.o.o.roche ltd. - tocilizumab - koncentrat za rastvor za infuziju - 400 mg/20 ml - 20 ml koncentrata za rastvor za infuziju sadrži: 400 mg tocilizumaba ( 20 mg/ml )
cinqaero
teva b.v. - reslizumab - astma - drugi sistemski lijekovi za opstruktivne plućne bolesti dišnih putova, - cinqaero je indiciran kao dodatna terapija u odraslih bolesnika s teškom astmom eozinofilni glikemija unatoč visokom dozom udahnuti kortikosteroidi plus još jedan lijek za terapiju održavanja.